IDXX IDEXX (IDXX) Q4 FY24 earnings call
IDEXX delivered a solid Q4 FY24, exceeding expectations with 6% organic revenue growth, driven by strong international performance and new product launches like inVue Dx and Cancer Dx. Despite persistent declines in U.S. clinical visits, the company achieved a significant growth premium, supported by innovation and commercial execution. Management is focused on leveraging its robust pipeline and expanding global footprint to drive future growth, while navigating macroeconomic pressures.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
IDXX operating KPIs by quarter
| KPI | This call Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|---|---|
| Premium instrument placements | 4,625In the fourth quarter, we placed 4,625 premium instruments, down 12% from high prior year levels.Source: earnings call transcript | 4,163During Q1, we placed 4,163 CAG premium instruments, a decline of 13% against high prior-year levels.Source: earnings call transcript | 6,070Total premium placements reached 6,070 units, an increase of 23% year-over-year.Source: earnings call transcript | 5,665Total premium placements reached 5,665 units, an increase of 37% year-over-year.Source: earnings call transcript | 6,567In the fourth quarter, we placed 6,567 premium instruments, up 42% from the prior year.Source: earnings call transcript | 4,650CAG premium instrument placements reached 4,650 units during the first quarter, an increase of 12% year-over-year and the quality of placements remains superb reflected in over 1,000 global new and competitive catalyst placements, including nearly 320 in North America.Source: earnings call transcript | 5,265CAG premium instrument placements reached 5,265 units during the second quarter resulting in an expected year-over-year decline as we lap the broad commercial availability of inVue Dx in the prior year.Source: earnings call transcript | +13.2% |
| Employees | <11KI extend my deepest gratitude to our nearly 11,000 employees whose dedication and hard work have made these accomplishments possible.Source: earnings call transcript | — | 11KAs I conclude our prepared remarks, I want to express my deep appreciation for our 11,000 IDEXX employees worldwide.Source: earnings call transcript | 11KAs we conclude, I want to extend my deep gratitude to our 11,000 IDEXX employees worldwide.Source: earnings call transcript | 11KI want to close by thanking our 11,000 employees around the world.Source: earnings call transcript | ~11KOur approximately 11,000 IDEXX employees around the world are purpose-driven and our talent fuels the company's growth.Source: earnings call transcript | — | — |
| IDEXX InVue Dx instrument placements | — | — | — | 1,753Globally, we placed 1,753 IDEXX InVue Dx instruments as we continue to meet customer demand for this highly innovative analyzer.Source: earnings call transcript | 1,900+We achieved record premium instrument placements in Q4, with strong gains across our major platforms, including over 1,900 IDEXX inVue Dx placements, supporting a 69% organic year-over-year expansion of our CAG Diagnostic instrument revenues.Source: earnings call transcript | 1,100Strong premium instrument placements in the quarter resulted in 28% organic growth of CAG instrument revenues and included 1,100 IDEXX inVue Dx analyzers.Source: earnings call transcript | 1,602Globally, we placed 1,602 IDEXX inVue Dx instruments in Q2 and over 1,000 new and competitive catalyst instruments globally with nearly 300 in the US IDEXX global reference lab revenues increased over 10% organically in Q2, led by volume gains.Source: earnings call transcript | +45.6% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.